Infliximab treatment in ankylosing spondylitis: an observational study
| dc.contributor.author | Nikas, S. N. | en |
| dc.contributor.author | Alamanos, Y. | en |
| dc.contributor.author | Voulgari, P. V. | en |
| dc.contributor.author | Pliakou, X. I. | en |
| dc.contributor.author | Papadopoulos, C. G. | en |
| dc.contributor.author | Drosos, A. A. | en |
| dc.date.accessioned | 2015-11-24T19:10:06Z | |
| dc.date.available | 2015-11-24T19:10:06Z | |
| dc.identifier.issn | 0003-4967 | - |
| dc.identifier.uri | https://olympias.lib.uoi.gr/jspui/handle/123456789/20789 | |
| dc.rights | Default Licence | - |
| dc.subject | Adult | en |
| dc.subject | Aged | en |
| dc.subject | Antibodies, Monoclonal/adverse effects/*therapeutic use | en |
| dc.subject | Antirheumatic Agents/adverse effects/*therapeutic use | en |
| dc.subject | Female | en |
| dc.subject | Follow-Up Studies | en |
| dc.subject | Humans | en |
| dc.subject | Male | en |
| dc.subject | Middle Aged | en |
| dc.subject | Neoplasm Proteins/therapeutic use | en |
| dc.subject | Receptors, Tumor Necrosis Factor, Type II | en |
| dc.subject | Severity of Illness Index | en |
| dc.subject | Spondylitis, Ankylosing/*drug therapy | en |
| dc.subject | Treatment Outcome | en |
| dc.subject | Tumor Necrosis Factor Decoy Receptors | en |
| dc.title | Infliximab treatment in ankylosing spondylitis: an observational study | en |
| heal.abstract | OBJECTIVE: To investigate efficacy, toxicity, and drug discontinuation in patients with ankylosing spondylitis (AS) treated with infliximab. METHODS: 35 patients with AS with mean (SD) age 42.5 (12.6) years and mean (SD) disease duration 14.5 (8.0) years were studied for 2 years. Patients entering the study had a negative tuberculin skin test, were fully informed about the treatment, and were followed up regularly. Infliximab, 5 mg/kg weight, was given intravenously at weeks 0, 2, 6, and every 8 weeks thereafter. Data concerning infliximab tolerability, adverse events, interval, and drug discontinuation were all recorded. Clinical improvement according to the BASDAI and the Ankylosing Spondylitis Assessment Study group (ASAS) 20%, 40%, and ASAS 5/6 response criteria were recorded. RESULTS: After 1 year, 20 (57%) patients achieved the BASDAI 50% response criteria, 25 (71%) achieved ASAS 20%, 23 (66%) reached ASAS 40%, and 18 (51%) attained ASAS 5/6. After 2 years' treatment, 11 (31%) patients achieved BASDAI 50% response criteria, 14 (40%) ASAS 20%, 11 (31%) ASAS 40%, and 9 (26%) ASAS 5/6. Clinical improvement was associated with an improved BASFI and reduction of CRP. After 2 years' treatment, "infliximab survival" was 89%. Treatment was well tolerated and adverse events were mild; 3 patients discontinued the study. CONCLUSION: Infliximab was effective, safe, and well tolerated in patients with AS. | en |
| heal.access | campus | - |
| heal.fullTextAvailability | TRUE | - |
| heal.identifier.primary | 10.1136/ard.2004.029900 | - |
| heal.identifier.secondary | http://www.ncbi.nlm.nih.gov/pubmed/15564309 | - |
| heal.identifier.secondary | http://ard.bmj.com/content/64/6/940.full.pdf | - |
| heal.journalName | Ann Rheum Dis | en |
| heal.journalType | peer-reviewed | - |
| heal.language | en | - |
| heal.publicationDate | 2005 | - |
| heal.recordProvider | Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής | el |
| heal.type | journalArticle | - |
| heal.type.el | Άρθρο Περιοδικού | el |
| heal.type.en | Journal article | en |
Αρχεία
Φάκελος/Πακέτο αδειών
1 - 1 of 1
Φόρτωση...
- Ονομα:
- license.txt
- Μέγεθος:
- 1.74 KB
- Μορφότυπο:
- Item-specific license agreed upon to submission
- Περιγραφή: